Thrombolytic therapy for submassive/intermediate risk Pulmonary Embolism Evidence and suggestions after PEITHO trial

被引：1

作者：

Marin V., Arnaldo ^{[1
]}

Tomas Gazmuri B., Jose ^{[2
]}

Andresen V., Max ^{[4
]}

Andresen, Max ^{[3
]}

机构：

[1] Univ Chile, Fac Med, Hosp Clin Univ Chile, Med Interna, Santiago 7, Chile

[2] Univ Los Andes, Fac Med, Med Interna, Santiago, Chile

[3] Pontificia Univ Catolica Chile, Fac Med, Dept Med Intens, Santiago, Chile

[4] Pontificia Univ Catolica Chile, Fac Med, Interno Med, Santiago, Chile

来源：

REVISTA MEDICA DE CHILE | 2015年 / 143卷 / 07期

关键词：

Pulmonary embolism; Shock; Thrombectomy; Thrombolytic therapy; RIGHT-VENTRICULAR DYSFUNCTION; TISSUE PLASMINOGEN-ACTIVATOR; MULTICENTER DOUBLE-BLIND; INTRACRANIAL HEMORRHAGE; PROGNOSTIC VALUE; MANAGEMENT; ALTEPLASE; OUTCOMES; HEPARIN; TENECTEPLASE;

D O I：

10.4067/S0034-98872015000700011

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Therapy for submassive pulmonary embolism (intermediate risk), remains controversial. New evidence has appeared that may help us in the process of decision making. We review the relevant literature, outline prognostic factors, and discuss current recommendations and controversies regarding the available alternatives such as systemic and catheter-directed thrombolytic use.

引用

页码：895 / 904

页数：10

共 50 条

[41] Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial
Stefano Barco
Mariaconcetta Russo
Eric Vicaut
Cecilia Becattini
Laurent Bertoletti
Jan Beyer-Westendorf
Hélène Bouvaist
Francis Couturaud
Thierry Danays
Claudia Dellas
Daniel Duerschmied
Klaus Empen
Emile Ferrari
Nazzareno Galiè
David Jiménez
Frederikus A. Klok
Maciej Kostrubiec
Matija Kozak
Christian Kupatt
Irene M. Lang
Mareike Lankeit
Nicolas Meneveau
Massimiliano Palazzini
Piotr Pruszczyk
Matteo Rugolotto
Aldo Salvi
Olivier Sanchez
Sebastian Schellong
Bozena Sobkowicz
Guy Meyer
Stavros V. Konstantinides
Clinical Research in Cardiology, 2019, 108 : 772 - 778
[42] Echocardiographic assessment with right ventricular function improvement following ultrasound-accelerated catheter-directed thrombolytic therapy in submassive pulmonary embolism
Doheny, Charles
Gonzalez, Lorena
Duchman, Stanley M.
Varon, Joseph
Bechara, Carlos F.
Cheung, Mathew
Lin, Peter H.
VASCULAR, 2018, 26 (03) : 271 - 277
[43] Point: Should Systemic Lytic Therapy Be Used for Submassive Pulmonary Embolism? Yes
Jimenez, David
CHEST, 2013, 143 (02) : 296 - 299
[44] The Results of Thrombolytic Treatment in Patients With High risk Pulmonary Embolism
Atas, Ali Ekber
Sarac, Atilla
Dirican, Adem
Topbasi, Nazli
Uzar, Tuqce
Rastgar, Ladan
Ekaterina, Pankina
Ozkaya, Sevket
JOURNAL OF CARDIOVASCULAR EMERGENCIES, 2019, 5 (03): : 92 - 98
[45] Thrombolytic therapy for pulmonary embolism - Frequency of intracranial hemorrhage and associated risk factors
Kanter, DS
Mikkola, KM
Patel, SR
Parker, JA
Goldhaber, SZ
CHEST, 1997, 111 (05) : 1241 - 1245
[46] Thrombolytic Therapy for Acute Pulmonary Embolism
Tapson, Victor F.
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2013, 39 (04) : 452 - 458
[47] Predictors of pulmonary hypertension after intermediate-to-high risk pulmonary embolism
Barros, Andre
Baptista, Rui
Nogueira, Antony
Jorge, Elisabete
Teixeira, Rogerio
Castro, Graca
Monteiro, Pedro
Augusto Providencia, Luis
REVISTA PORTUGUESA DE CARDIOLOGIA, 2013, 32 (11) : 857 - 864
[48] Risk assessment and management of high and intermediate risk pulmonary embolism
Meyer, Guy
Sanchez, Olivier
Jimenez, David
PRESSE MEDICALE, 2015, 44 (12): : E401 - E408
[49] Best evidence in critical care medicine - Treatment of submassive pulmonary embolism
McDermid, RC
CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE, 2004, 51 (08): : 846 - 847
[50] The role of thrombolytic therapy in pulmonary embolism
Wang, Tzu-Fei
Squizzato, Alessandro
Dentali, Francesco
Ageno, Walter
BLOOD, 2015, 125 (14) : 2191 - 2199

← 1 2 3 4 5 →